- Stealth BioTherapeutics Corp (NASDAQ:MITO) will be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd and J. Wood Capital Advisors LLC in an all-cash transaction.
- Each Stealth Bio will be canceled and cease to exist for the right to receive $0.03125 in cash. Each American Depositary Share representing 12 shares will be canceled for the right to receive $0.375.
- Related: Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candidate.
- The merger consideration represents a premium of 34.4% to the closing price on June 24, the last trading day before the company announced its receipt of the original “going-private” proposal.
- The merger is expected to close during the second half of 2022.
- Price Action: MITO shares are up 19.6% at $0.29 during the market session on the last check Monday.
Aptorum Group Announces Publication Of A Co-Authored Paper On Its PathsDx Technology, A Rapid-Turnaround Low-Depth Unbiased Metagenomics Sequencing Workflow For Liquid Biopsy Based Diagnosis Of Infectious Diseases On Illumina Platforms
Regulatory News:
Aptorum Group Limited (NASDAQ:APM, PARIS:APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs in oncology, autoimmune and infectious diseases, is pleased to announce
